Please use this identifier to cite or link to this item: https://hdl.handle.net/10356/155760
Title: Telacebec : an investigational antibacterial for the treatment of tuberculosis (TB)
Authors: Lee, Bei Shi
Pethe, Kevin
Keywords: Science::Biological sciences::Biochemistry
Issue Date: 2022
Source: Lee, B. S. & Pethe, K. (2022). Telacebec : an investigational antibacterial for the treatment of tuberculosis (TB). Expert Opinion On Investigational Drugs, 31(2), 139-144. https://dx.doi.org/10.1080/13543784.2022.2030309
Project: NRF-NRFI06-2020- 0004
NRF-CRP18-2017-01
Journal: Expert Opinion on Investigational Drugs
Abstract: Introduction: Tuberculosis is an infectious disease that affected more than 50 million people and killed 6.7 million patients in the past 5 years alone. Additionally, rising incidence of treatment resistance threatens the global effort to eradicate this disease. With limited options available, additional novel antibiotics are needed for the treatment of multidrug-resistant tuberculosis (MDR-TB). Telacebec is a first-in-class antibiotic that targets the pathogen’s energy metabolism. Areas covered: This paper provides an overview of the recent progress in the development and testing of telacebec. We discuss published clinical data and examine the design and setup of its clinical trials. We also offer insights on the therapeutic potential of telacebec and aspects of which should be evaluated in the future. Expert opinion: The first phase 2a trial showed a correlation between dosage and bacterial load in patient sputum, which should be confirmed using a direct measurement method such as colonyforming unit counting. Its clinical efficacy, favorable pharmacokinetic properties, low arrhythmogenic risk, and activity against MDR-TB strains make telacebec a suitable candidate for further development. Future clinical testing in combination with approved second-line drugs will reveal its full potential against MDR-TB. Considering recent preclinical studies, we also recommend initiating clinical trials for Buruli ulcer and leprosy.
URI: https://hdl.handle.net/10356/155760
ISSN: 1354-3784
DOI: 10.1080/13543784.2022.2030309
Rights: This is an Accepted Manuscript of an article published by Taylor & Francis in Expert Opinion on Investigational Drugs on 26 Jan 2022, available online: http://www.tandfonline.com/10.1080/13543784.2022.2030309.
Fulltext Permission: embargo_20230203
Fulltext Availability: With Fulltext
Appears in Collections:LKCMedicine Journal Articles
SBS Journal Articles

Files in This Item:
File Description SizeFormat 
EOID article FINAL.pdf
  Until 2023-02-03
325.52 kBAdobe PDFUnder embargo until Feb 03, 2023

Page view(s)

43
Updated on Jul 2, 2022

Google ScholarTM

Check

Altmetric


Plumx

Items in DR-NTU are protected by copyright, with all rights reserved, unless otherwise indicated.